Profound Medical (PROF) Stock Price, News & Analysis

Company Overview

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia. The system features a closed-loop control mechanism that precisely adjusts ultrasound energy delivery based on continuous feedback from MR temperature mapping, enabling controlled ablation of prostate tissue while preserving surrounding structures.

Founded in 2015, Profound Medical has secured regulatory approvals and clearances in multiple jurisdictions, including CE mark certification for the European market and FDA clearance in the United States. The company has established a network of clinical partners and distributors across North America and Europe, where its technology is being adopted in leading cancer centers and urology clinics.

Profound Medical’s leadership comprises professionals with extensive experience in medical device development, clinical operations and regulatory affairs. The company continues to invest in research and development to expand its ultrasound platform for additional therapeutic indications and to support ongoing clinical studies aimed at improving patient outcomes.

Key Stats

• Today's Range: $3.76 to $4.11
• 50-Day Range: $3.87 to $6.09
• 52-Week Range: $3.76 to $9.17
• Volume: 70,679 shs
• Average Volume: 171,636 shs
• Market Capitalization: $116.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Profound Medical Stock Analysis - MarketRank™

Profound Medical scored higher than 32% of companies evaluated by MarketBeat, and ranked 690th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Profound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Profound Medical has a consensus price target of $11.00, representing about 184.2% upside from its current price of $3.87.

Amount of Analyst Coverage

Profound Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Profound Medical are expected to grow in the coming year, from ($1.12) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Profound Medical is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Profound Medical is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Profound Medical has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.07% of the outstanding shares of Profound Medical have been sold short.

Short Interest Ratio / Days to Cover

Profound Medical has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Profound Medical has recently decreased by 2.76%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Profound Medical does not currently pay a dividend.

Dividend Growth

Profound Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.07% of the outstanding shares of Profound Medical have been sold short.

Short Interest Ratio / Days to Cover

Profound Medical has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Profound Medical has recently decreased by 2.76%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Profound Medical this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Profound Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.52% of the stock of Profound Medical is held by insiders.

Percentage Held by Institutions

47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PROF Stock Analysis - Frequently Asked Questions

How have PROF shares performed this year?

Profound Medical's stock was trading at $7.51 at the beginning of 2025. Since then, PROF stock has decreased by 48.5% and is now trading at $3.87.

How were Profound Medical's earnings last quarter?

Profound Medical (NASDAQ:PROF) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.09. The company had revenue of $2.21 million for the quarter, compared to analysts' expectations of $4.75 million. Profound Medical had a negative trailing twelve-month return on equity of 89.74% and a negative net margin of 343.97%.
Read the conference call transcript.

Who are Profound Medical's major shareholders?

Top institutional investors of Profound Medical include Gagnon Securities LLC (5.82%), Letko Brosseau & Associates Inc. (4.01%), Raymond James Financial Inc. (3.13%) and Timelo Investment Management Inc. (2.80%).
View institutional ownership trends.

How do I buy shares of Profound Medical?

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Profound Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PROF
• CIK: 1628808
• Web: www.profoundmedical.com
• Phone: (647) 476-1350
• Fax: 64-7847-3739
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Profound Medical: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +184.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.82 million
• Net Margins: -343.97%
• Pretax Margin: -343.61%
• Return on Equity: -89.74%
• Return on Assets: -73.06%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 8.53
• Quick Ratio: 7.07

Sales & Book Value

• Annual Sales: $10.68 million
• Price / Sales: 10.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.01 per share
• Price / Book: 1.93

Miscellaneous

• Outstanding Shares: 30,050,000
• Free Float: 29,596,000
• Market Cap: $116.29 million
• Optionable: Optionable
• Beta: 0.55